What is the role of antibiotic therapy in the treatment of coronary artery atherosclerosis?

Updated: Apr 09, 2021
  • Author: Sandy N Shah, DO, MBA, FACC, FACP, FACOI; Chief Editor: Yasmine S Ali, MD, MSCI, FACC, FACP  more...
  • Print

Although inflammation is considered to be a risk factor for the development of atherosclerosis, antibiotic therapy does not appear to have a significant role in secondary prevention of this disorder. Several multicenter trials have evaluated the effect of antibiotic therapy on recurrent cardiac events when used as secondary prevention. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infarction with Chlamydia (ACADEMIC) trial, [83] the Azithromycin in Acute Coronary Syndrome (AZACS) study, [84] the South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA), [85] the Azithromycin Coronary Events Study (ACES), [86] and the antibiotic arm of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial [87] all returned negative results in terms of any significant benefit from antibiotic therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!